Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Repare Therapeutics Inc
(NQ:
RPTX
)
3.010
+0.040 (+1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Repare Therapeutics Inc
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 01, 2022
Gainers
Via
Benzinga
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
June 01, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
30 Stocks Moving In Monday's Mid-Day Session
May 23, 2022
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday.
Via
Benzinga
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
April 12, 2022
Via
Benzinga
58 Biggest Movers From Yesterday
May 24, 2022
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Via
Benzinga
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
May 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
April 20, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2022
April 12, 2022
Upgrades
Via
Benzinga
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
April 11, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
April 08, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients
March 07, 2022
Repare Therapeutics Inc (NASDAQ: RPTX) has announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR trial of RP-3500....
Via
Benzinga
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
February 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
January 07, 2022
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...
Via
Benzinga
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
January 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
January 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
December 21, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
December 15, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
November 15, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 02, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
October 27, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Proposed Public Offering of Common Shares
October 27, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
October 18, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting
October 11, 2021
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid...
Via
Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.